Literature DB >> 29396817

Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition.

Yamila Goenaga-Vázquez1, Gloria Colón2, Nilka Barrios2, María Correa3.   

Abstract

Renal medullary carcinoma (RMC) is a highly aggressive and rare malignancy found almost exclusively in young patients with sickle cell trait (SCT). Metastatic disease is commonly present at diagnosis. There is very limited experience treating disseminated disease and the prognosis is dismal. We report the case of a young 9-year-old boy with SCT, who presented with 4 months' progression of abdominal pain, nausea and vomiting associated with cough spells, dysphagia, and weight loss. Upon evaluation, he was underweight, pale, and in mild respiratory distress. Cervical lymphadenopathy was evident and abdomen was diffusely tender. A whole-body CT scan showed a left kidney lesion with associated cervical, mediastinal, and retroperitoneal lymphadenopathy. Biopsy of a cervical lymph node revealed metastatic RMC. Patient was started on combination chemotherapy with paclitaxel, carboplatin, and gemcitabine followed by left adrenalectomy. In spite of having advanced disease, our patient achieved an excellent response with a progression-free survival of 17 months. Although SCT is thought to be a "benign" condition, RMC is one devastating complication associated with it. Considering its rarity, the near uniform associated fatality should prompt the question of whether clinical practice should change regarding proper counseling of these patients and raise awareness in the medical community.

Entities:  

Keywords:  Hematuria; Hemoglobinopathies; Kidney medulla; Renal medullary carcinoma; Sickle cell disease; Sickle cell trait; Sickling

Year:  2018        PMID: 29396817      PMCID: PMC5886939          DOI: 10.1007/s13730-018-0308-3

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  14 in total

Review 1.  Significant responses to platinum-based chemotherapy in renal medullary carcinoma.

Authors:  John J Strouse; Melissa Spevak; A Kyle Mack; Robert J Arceci; Donald Small; David M Loeb
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167

2.  Medullary renal cell carcinoma and response to therapy with bortezomib.

Authors:  Ellen A Ronnen; G Varuni Kondagunta; Robert J Motzer
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

3.  SMARCB1/INI1 inactivation in renal medullary carcinoma.

Authors:  Julien Calderaro; Julien Moroch; Gaelle Pierron; Florence Pedeutour; Camille Grison; Pascale Maillé; Pascale Soyeux; Alexandre de la Taille; Jérome Couturier; Annick Vieillefond; Marie Christine Rousselet; Olivier Delattre; Yves Allory
Journal:  Histopathology       Date:  2012-06-11       Impact factor: 5.087

4.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

Authors:  P J Loehrer; L H Einhorn; P J Elson; E D Crawford; P Kuebler; I Tannock; D Raghavan; R Stuart-Harris; M F Sarosdy; B A Lowe
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

5.  Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.

Authors:  Edward M Schaeffer; Thomas J Guzzo; Kyle A Furge; George Netto; Michael Westphal; Karl Dykema; Ximing Yang; Ming Zhou; Bin Tean Teh; Christian P Pavlovich
Journal:  BJU Int       Date:  2009-12-11       Impact factor: 5.588

6.  Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.

Authors:  Qingyan Liu; Susanna Galli; Ramaprasad Srinivasan; William Marston Linehan; Maria Tsokos; Maria J Merino
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

Review 7.  Renal medullary carcinoma: the Bronx experience.

Authors:  A Ari Hakimi; Phillip T Koi; Paul M Milhoua; Netta M Blitman; Maomi Li; Vladimir Hugec; Janice P Dutcher; Reza Ghavamian
Journal:  Urology       Date:  2007-11       Impact factor: 2.649

Review 8.  Renal medullary carcinoma and sickle cell trait: A systematic review.

Authors:  Ofelia Alvarez; Maria M Rodriguez; Lanetta Jordan; Sharada Sarnaik
Journal:  Pediatr Blood Cancer       Date:  2015-06-05       Impact factor: 3.167

9.  High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.

Authors:  W Kimryn Rathmell; J Paul Monk
Journal:  Urology       Date:  2008-07-23       Impact factor: 2.649

10.  Renal medullary carcinoma. The seventh sickle cell nephropathy.

Authors:  C J Davis; F K Mostofi; I A Sesterhenn
Journal:  Am J Surg Pathol       Date:  1995-01       Impact factor: 6.394

View more
  1 in total

Review 1.  Recent Advances in Renal Medullary Carcinoma.

Authors:  Yongdong Su; Andrew L Hong
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.